Pozen Inc. is seeking Food and Drug Administration approval of Vimovo. a new drug candidate intended to prevent gastric ulcers in patients with chronic pain. The drug is aimed to treat different forms of arthritis and combines AstraZeneca"s Nexium [esomerprazole magnesium] with the painkiller, Naproxen. When the application has been filed Pozen is to receive a $10 million payment from AstraZeneca PLC.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지